{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&_metadata=all&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1287491", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287491/answer", "answerText" : {"_value" : "<p>Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) are co-leads of the vaccines pillar of the Access to COVID-19 Technologies (ACT) Accelerator. The ACT-Accelerator is an initiative to support collaboration and resource mobilisation in accelerating the development of, and equitable access to new COVID-19 vaccines, treatments, and tests. In its COVID-19 Technology Access Pool (C-TAP) concept note, the World Health Organisation sets out that the ACT-Accelerator is a separate but complementary initiative to C-TAP.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-26T11:46:15.067Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Disease Control"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps the Government is taking to use its representation on the Boards of (a) Gavi, the Vaccines Alliance and (b) the Coalition for Epidemic Preparedness Innovations to assess how those organisations can support the operation of the WHO's COVID-19 Technology Access Pool.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "155234"}
    , {"_about" : "http://data.parliament.uk/resources/1287492", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287492/answer", "answerText" : {"_value" : "<p>Since the World Health Organisation (WHO) provided initial details on the COVID-19 technology access pool (C-TAP) in October 2020, the UK has, and will continue to engage with all interested parties. We are in ongoing discussions with the WHO as it refines both governance structures and the operating model for C-TAP, and will seek clarity on questions being posed by stakeholders.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-26T11:50:01.61Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Disease Control"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what further plans he has to consult on the WHO COVID-19 Technology Access Pool with (a) the pharmaceutical industry, (b) research institutions and (c) G7 members.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "155235"}
    , {"_about" : "http://data.parliament.uk/resources/1287493", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1287493/answer", "answerText" : {"_value" : "<p>The UK is one of the biggest global donors on COVID-19, and has pledged over £1 billion of UK aid to counter the health, humanitarian, and economic risks of the pandemic. To support global access to vaccines, we fund international organisations in delivering an 'end to end' approach to developing new vaccines, treatments, and tests, from research, development, and clinical trials through to supporting manufacturing scale-up and delivery. We report aid spend using standard Organisation for Economic Cooperation and Development (OECD) Development Assistance Committee codes, which do not track how much aid is spent on vaccine manufacturing specifically.<\/p><p>Building vaccine manufacturing capacity is a long-term, capital intensive, and high-risk endeavour. The UK is providing technical assistance to catalyse private sector and development finance investment into vaccine manufacturing in Africa, the region with the least manufacturing capacity globally. This includes engaging with the International Finance Corporation (IFC) to support business case development for their $4 billion Global Health Platform to support manufacturing of health essentials such as therapeutics, diagnostics, and vaccines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-26T16:10:05.54Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Development Aid: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, how much Official Development Assistance is spent annually by the Government on advancing vaccine manufacturing capabilities in low and middle-income countries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "155236"}
    , {"_about" : "http://data.parliament.uk/resources/1285580", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285580/answer", "answerText" : {"_value" : "<p>Ending the COVID-19 pandemic requires a global solution, which is why the UK is leading efforts for global equitable access to COVID-19 vaccines and treatments. This includes a £548 million contribution to the COVAX Advance Market Commitment to ensure that 92 low and middle income countries are able to access COVID-19 vaccines.<\/p><p>It is too early to determine if the UK will have excess vaccine supply. We continue to work with our international partners to drive the global response and save lives.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-23T15:43:07.173Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Developing Countries: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what the Government's plan is for redistributing covid-19 vaccine doses to other countries; and what the timescale is for that redistribution.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "152586"}
    , {"_about" : "http://data.parliament.uk/resources/1285581", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285581/answer", "answerText" : {"_value" : "<p>The UK is committed to rapid, equitable access to safe and effective vaccines. The UK has committed £548 million to the COVAX Advance Market Commitment (AMC), which is an international initiative whose volume guarantees encourage manufacturing capacity to be scaled up to produce and deliver vaccines at the scale needed to support global equitable access to vaccines.<\/p><p>The FCDO is working closely with key development partners in vaccines, such as the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, the World Health Organization (WHO) and the United Nations International Children's Emergency Fund (UNICEF), along with development finance institutions, regional institutions, and the private sector to catalyse investments into vaccine manufacturing in low- and middle-income countries.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-23T15:44:46.193Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Developing Countries: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps his Department is taking to support the scale-up of covid-19 vaccine manufacturing capacity in Low and Middle Income countries.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "152587"}
    , {"_about" : "http://data.parliament.uk/resources/1285582", "AnsweringBody" : [{"_value" : "Department for International Trade"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285582/answer", "answerText" : {"_value" : "<p>I refer the Hon. Member for Norwich South to the answer I gave to the Hon. Member for North East Fife on 25 November 2020, UIN: 115822.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1526", "label" : {"_value" : "Biography information for Greg Hands"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chelsea and Fulham"}
        , "answeringMemberPrinted" : {"_value" : "Greg Hands"}
        , "dateOfAnswer" : {"_value" : "2021-02-25", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-25T13:05:55.743Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "202"}
      , "answeringDeptShortName" : {"_value" : "International Trade"}
      , "answeringDeptSortName" : {"_value" : "International Trade"}
      , "date" : {"_value" : "2021-02-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "TRIPS Agreement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for International Trade, what the Government's policy is on the proposed WTO TRIPS Waiver and the use of that waiver by foreign Governments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "152588"}
    , {"_about" : "http://data.parliament.uk/resources/1284395", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284395/answer", "answerText" : {"_value" : "<p>The Government has made no such assessment and does not consider waiving intellectual property rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T17:26:12.45Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "TRIPS Agreement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has undertaken an impact assessment on public health implications for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149799"}
    , {"_about" : "http://data.parliament.uk/resources/1284396", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284396/answer", "answerText" : {"_value" : "<p>The UK Government does not consider waiving IP rights to be an appropriate course of action to boost the manufacturing of safe, effective and quality vaccines.<\/p><p> <\/p><p>The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies, to detect, treat and defend against COVID-19. The incentives and access mechanisms provided by the IP framework have been integral to this success, without which we would not have seen the impressive surge of R&amp;D and the unprecedented scaling up of production.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4372", "label" : {"_value" : "Biography information for Amanda Solloway"}
        }
        , "answeringMemberConstituency" : {"_value" : "Derby North"}
        , "answeringMemberPrinted" : {"_value" : "Amanda Solloway"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T17:51:37.377Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Intellectual Property"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, whether his Department has undertaken an impact assessment on potential economic costs for the UK in the event that the proposed World Trade Organisation TRIPS Waiver is not approved.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149800"}
    , {"_about" : "http://data.parliament.uk/resources/1284397", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284397/answer", "answerText" : {"_value" : "<p>The UK is committed to rapid equitable access to safe and effective vaccines, and is playing a leading role in financing the global effort, and identifying solutions that ensure affordable access for all.<\/p><p>The UK Government does not consider waiving intellectual property (IP) rights to be an appropriate course of action in boosting the manufacturing of safe, effective, and quality vaccines. The existing intellectual property framework has mobilised research and development to deliver a host of new medicines and technologies to detect, treat, and defend against COVID-19. The incentives and access mechanisms provided by the IP framework have been integral to this success, without which we would not have seen the impressive surge of research and development, and the unprecedented scaling up of production.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"}
        }
        , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"}
        , "answeringMemberPrinted" : {"_value" : "Wendy Morton"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T09:33:49.997Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "208"}
      , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment the Government has made of the effect on global equality of access to the covid-19 vaccines in the event that the proposed WTO TRIPS Waiver is not adopted.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149801"}
    , {"_about" : "http://data.parliament.uk/resources/1284399", "AnsweringBody" : [{"_value" : "Department for International Trade"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1284399/answer", "answerText" : {"_value" : "<p>The UK has engaged regularly in debates at the World Trade Organisation (WTO) TRIPS Council and other international institutions to promote affordable and equitable global access to COVID-19 vaccines, including in developing countries. We respect the informal format of WTO discussions and do not publish proceedings from those meetings. However, at the informal TRIPS Council on 4 February 2021, the UK sought to further understand the parameters of the proposed waiver and asked for clarifications from the waiver\u2019s proponents. This remains consistent with the Government\u2019s approach to encourage evidence-based discussions between WTO Members to find solutions to present issues within the multilateral intellectual property framework.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1526", "label" : {"_value" : "Biography information for Greg Hands"}
        }
        , "answeringMemberConstituency" : {"_value" : "Chelsea and Fulham"}
        , "answeringMemberPrinted" : {"_value" : "Greg Hands"}
        , "dateOfAnswer" : {"_value" : "2021-02-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-15T11:53:53.13Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "202"}
      , "answeringDeptShortName" : {"_value" : "International Trade"}
      , "answeringDeptSortName" : {"_value" : "International Trade"}
      , "date" : {"_value" : "2021-02-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "TRIPS Agreement"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for International Trade, if she will publish statements made by the Government related to the proposed TRIPS Waiver at the World Trade Organisation TRIPS Council Meeting on 4 February 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4500", "label" : {"_value" : "Biography information for Clive Lewis"}
      }
      , "tablingMemberConstituency" : {"_value" : "Norwich South"}
      , "tablingMemberPrinted" : [{"_value" : "Clive Lewis"}
      ], "uin" : "149802"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-answer.questionFirstAnswered.=2019-07-05T11%3A23%3A04.133Z&tablingMemberConstituency=Norwich+South&max-answer.questionFirstAnswered.=2021-02-26T16%3A10%3A05.54Z", "page" : 0, "startIndex" : 1, "totalResults" : 93, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}